CAR-T therapies that are being developed by Bristol Myers Squibb and Janssen have all hit targets in early-mid-stage trials. Increasing hopes of new treatment options for difficult to treat blood cancers. Johnson & Johnson’s Janssen unveiled initial results from the Phase Ib/II CARTITUDE-1 study assessing the efficacy and safety of JNJ-68284528 (JNJ-4528) – an investigational B cell
Bristol-Myers Squibb Company and Nektar Therapeutics have announced a new clinical collaboration to evaluate combining Bristol-Myers Squibb’s Opdivo with Nektar’s investigational medicine, NKTR-214, as a potential treatment regimen in five different tumour types and seven potential indications. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression. Whilst NKTR-214 is an investigational immuno-stimulatory
Celgene and Bristol-Myers Squibb have founded a clinical trial alliance for a potential new cancer combination therapy. As part of the alliance, the two companies will conduct a Phase I clinical study to assess the safety, tolerability and early efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo and Celgene’s chemotherapy Abraxane.
US regulatory body, the Food and Drug Administration (FDA), have granted breakthrough therapy status to Bristol-Myers Squibb and AbbVie’s elotuzumab to treat multiple myeloma (MM). The designation has been granted by the FDA for elotuzumab’s use with lenalidomide and dexamethasone in patients who have previously received one or more therapies to treat multiple myeloma. Elotuzumab
Patients with diabetes in Scotland have gained routine access to AstraZeneca/ Bristol-Myers Squibb’s Forxiga on the UK National Health Service (NHS) after it was considered cost-effective by the Scottish Medicines Consortium (SMC). The SMC have dispensed guidance to healthcare professionals approving the use of the first-in-class drug Forxiga (BMS-512148) in adults with type 2 diabetes
Bristol-Myers Squibb (B-MS) yesterday announced that they have completed their $5 billion purchase of Amylin and its diabetes franchise, meaning they can now progress onto a planned marketing alliance with drug giant AstraZeneca. The New York-based drug maker, who agreed to buy Amylin on the 1st July, confirmed that they have now successfully finalised their
A new indication for Bristol-Myers Squibb (BMS) and Eli Lilly’s Erbitux, which is sold outside the USA by Merck KGaA, has been approved by US regulators. Meanwhile, the US Food and Drug Administration (FDA) have also cleared the first KRAS companion diagnostic test, the therascreen KRAS diagnostic kit which was developed by the Netherlands-based firm,
Bristol-Myers Squibb have entered into a clinical collaboration agreement with Tibotec Pharmaceuticals, one of the Janssen Pharmaceutical Companies, to assess the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, combined with Tibotec Pharmaceuticals’ investigational NS3 protease inhibitor, TMC435, for the treatment of chronic hepatitis C virus (HCV). Within the agreement, the two
AstraZeneca and Bristol-Myers Squibb are celebrating after European regulators approved two of their diabetes drugs. AstraZeneca and Bristol-Myers Squibb Company announced today that the European Commission has granted marketing authorisation for Komboglyze, which combines the DPP-4 inhibitor Onglyza (saxagliptin) with metformin in a once-a-day tablet. The combination is to be used as an adjunct to
Bristol-Myers Squibb has signed an innovative strategic partnership with Aslan Pharmaceuticals, headquartered in Singapore, which will see Aslan help develop one of the US major’s investigational cancer compounds. The drug in question, BMS-777607, is a small molecule inhibitor of the MET receptor tyrosine kinase for the treatment of solid tumours. Under the terms of the
